Call for Abstracts

Call for Abstracts

We are calling for submissions of short abstracts in support of your Oral or Poster presentation at the Congress. Detailed instructions are available below.

Invitation

The 2022 Congress aims to bring together leading academic scientists, researchers and medical clinicians from all fields of oncology to exchange and share their experiences and research results with emphasis on tumour markers and their role in diagnosis and therapy.

Relevant new findings in research, diagnosis and clinical Oncology – as well as technical developments, standardization and quality control, will be presented by opinion leaders in Oral and Poster presentations, along with panel discussions and special topic seminars. In addition, as during recent years, the EGTM (European Group of Tumour Markers) will present their Guidelines on optimal use of Tumour Markers and their clinical interpretation.

General Abstract Format Information

These details will be asked of you once you start the submission process. Please review this list and make sure you have all the required answers before starting the submission process.

General required information and format restrictions

Abstract Title — do not exceede the 150 characters upper limit (approx. 20-25 words).

Authors and Affiliations:

  • Identify all authors with full affiliation (institution, address and country), name, and last name are required fields;
  • Identification of the Presenting author (will receive an invitation email to upload presentation/poster a few weeks before the Congress);
  • Identification of the Corresponding author (will receive all correspondence concerning the submission).
  • Do not abbreviate Department, Institute, University, etc. Text should be in Title Case.

Body of abstract — limited to a maximum of 360 words. Abbreviations must be defined upon first use and avoided in the title.

The Abstract format should include:

  • Background:
  • Study Aims:
  • Materials and Methods:
  • Results:
  • Conclusions:

Keywords — this call for papers does not accept keywords with submissions.

Classification — Please choose the appropriate topic (closest to your field of research your work belongs to) in order to aid the review process and programme formation.

ISOBM 2022 Topics

  • Liquid biopsy
  • Cancer genetics
  • Immunological markers of cancer
  • Prostate cancer
  • Bladder cancer
  • Gastrointestinal cancers
  • Lung cancer
  • Breast cancer
  • Ovarian cancer
  • Endometrial cancer
  • Hematological cancers
  • Cancer general
  • Biobanking

Additional requested information

Please indicate your preferred type of presentation:

  • Oral
  • Oral or Poster (no preference)
  • Poster
  • Invited lecture – to be selected by invited speakers only

Invitation letter for Visa required (presenting author):

  • Yes
  • No

Important notes to observe

  • All abstracts must contain original work that has not been published or presented on previous occasions.
  • Abstracts must be submitted in English.
  • Please check spelling and grammar carefully. All abstracts will be published as submitted.
  • Abstract Limit: A participant can be the Presenting Author of 2 Abstracts only.
  • The Submitting Author is required to ensure that all co-authors are aware of the content of the Abstract, before submission.
  • Correspondence related to the submitted abstract will be sent to the Submitting, Presenting, and Corresponding Authors only.
  • Registration of the Presenting author is mandatory. In order to ensure inclusion in the program, the Presenting author is required to register by September 1, 2022.

Visa Information — Abstracts submitted from outside the Schengen Area

International abstract submitters who plan to attend the 46th ISOBM Congress may need to apply for a VISA to travel to the meeting in Bled, Slovenia (EU). For more information on visa requirements, please go to https://www.schengenvisainfo.com/. Please be aware that the time required to obtain a VISA may be substantial. A letter confirming the Presenting author is to present at the Congress will be sent to abstract submitters that have checked “Yes” that a letter is needed.